Surface markers for the murine oval cell response by �끂�썝�긽
Surface Markers for the Murine Oval Cell Response
Craig Dorrell, Laura Erker, Kelsea M. Lanxon-Cookson, Stephanie L. Abraham, Tristan
Victoroff, Simon Ro, Pamela S. Canaday, Philip R. Streeter, and Markus Grompe
Oregon Health & Science University and the Oregon Stem Cell Center, Portland, OR
Abstract
The biology of progenitor activation in the liver is of considerable medical and scientific interest.
The powerful genetic tools available for the mouse make it an ideal model system to study this
complex process involving many different cell types. However, reagents for the isolation and
study of distinct hepatic subpopulations have been quite limited compared to those available for
hematopoietic cells. To produce cell surface reactive reagents more specific for the oval cell
response, we generated a new collection of monoclonal antibodies by immunization of Fischer rats
with enzymatically dispersed nonparenchymal cells from the livers of adult mice treated with 3,5-
diethoxycarbonyl-1,4-dihydrocollidine. Each of the resulting antibodies recognized a surface
antigen present on a liver cell subset and permitted the viable isolation of the associated
subpopulation by fluorescence-activated cell sorting. Differential activity was observed on normal
liver cells and at different stages of oval cell activation, indicating potential utility for progenitor
cell identification. The subdivision of liver cells using these tools should facilitate the study of the
biology of ductal and periductal hepatic cell types, including progenitors.
Conclusion—A new panel of surface reactive monoclonal antibodies to support investigation of
the murine oval cell response has been developed.
The liver contains facultative stem cells which can be activated in response to specific kinds
of injury.1 Although most hepatic regeneration is progenitor independent, liver stem cells
are of great interest in regards to chronic liver diseases2,3 and may play an important role in
some forms of liver cancer.4,5 Liver stem cell activation was first described in the rat, where
chemical damage in combination with partial hepatectomy caused the emergence of a new
cell type described according to its nuclear morphology as an oval cell.6 These cells are
thought to be bipotential progenitors capable of yielding both hepatocytes and bile ducts.
Despite the probable importance of the oval cell response in various pathological conditions,
little is known about the molecular regulation of this process. In particular, it is not known
whether the oval cell lineage is homogeneous or whether there are different kinds of hepatic
progenitors. The nature of the cell which gives rise to the oval cells, that is, the putative
hepatic stem cell, is unknown. An important reason for the lack of information regarding
these processes is the complexity of the cellular composition of the liver, particularly during
injury. Many different cell types are present including various kinds of hepatocytes, ducts,
hematopoietic cells, endothelial cells, macrophages, stellate cells, and others.7
To understand the complex cross-talk between the different cell types and analyze their
biological properties in detail, markers are needed to track them at the single-cell level.
Although various histological markers exist and have been used for years, the tools to
dissociate the liver into its constituent cell types and perform assays on particular cell
populations has been rather limited. In contrast, surface markers are abundant for
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hematopoietic cells and have been essential for the exploration of the biology of this system.
8,9 Several reports have used commercially available antibodies that recognize
hematopoietic surface markers to isolate hepatic subpopulations and perform biological
assays. In addition, a targeted effort was made to find markers that identify oval cells in the
rat.10,11 These antibodies (particularly OV-1, which recognizes a surface antigen) have
proven very useful in the study of progenitor biology in this animal. Recently, several
models of oval cell activation have been developed for the mouse, an organism that is much
more genetically tractable than the rat.3,12,13 Unfortunately, few tools are available to
identify and isolate cells emerging during the murine oval cell response. In particular,
reagents targeting surface markers are lacking. The most widely used tool for murine oval
cell identification is the monoclonal antibody A6.14 Unfortunately, A6 does not bind a cell
surface marker and thus cannot be used for viable cell isolation. Several hematopoietic
markers such as c-kit (the receptor for stem cell factor), Sca-1 (stem cell antigen 1), Thy1
(CD90), and CD34 have been used in the mouse, but none of these specifically labels liver
cell populations.15–17
To overcome this barrier to the study of oval cell response in the mouse, we developed a
panel of monoclonal antibodies which react preferentially with hepatic but not
hematopoietic cells. Here, we present the initial characterization of a panel of nine such
surface marker–specific reagents and demonstrate their utility in cell fractionation.
Materials and Methods
Tissue Sources and Liver Cell Isolation
Liver cells were obtained from c129/S3 mice fed a Purina 5015 diet with or without
supplementation with 0.1% wt/wt DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine, also
known as DDTPDC [diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-pyridine dicarboxylate];
Sigma-Aldrich and Harlan Tek-lad) for 2–3 weeks. Animal handling was described by
protocol A268 of the institutional review committee at Oregon Health & Science University.
Optimal preparation of a single-cell suspension of nonparenchymal liver tissue required a
substantially modified version of the protocol described by Wang et al.18 In order to recover
a representative sample of viable liver cells, a series of increasingly aggressive enzymatic
digests was employed. Initially, a standard mouse liver perfusion19 and hepatocyte isolation
was performed. Remaining solid liver tissue was subjected to sequential digests (20 minutes
each) of 2.5 mg/mL collagenase D (Sigma-Aldrich), 10 mg/mL collagenase D + 10 mg/mL
pronase (Sigma-Aldrich), and a 10-minute digest with 0.05% trypsin/ethylene diamine
tetraacetic acid (Promega). At each stage, dissociated cells were collected by passage
through a 40 μm cell strainer (BD Falcon) and stored without further exposure to enzyme.
Incompletely dissociated tissue/cell clusters were recovered from the strainer and exposed to
the next digestion solution. Hepatocytes were excluded from nonparenchymal cell (NPC)
preparations by repeated low-speed (50g) centrifugations.
For immunohistochemical screening, livers were collected from mice on control or DDC-
supplemented diets for 3 weeks. Portions were embedded in Tissue-tek cry-omatrix (Sakura,
Tokyo, Japan) and stored at −86°C prior to cryosectioning.
Antibody Production
Animal care and immunization procedures were performed in accordance with protocols
A982 of the institutional review committee at Oregon Health & Science University. A
modified subtractive immunization protocol20 was employed. Specifically, a Fisher 344 rat
was preimmunized with undesirable antigens including 1 × 106 hepatocytes, fetal bovine
serum (FBS), and small amounts of collagenase D. Cyclo-phosphamide (Sigma-Aldrich; 51
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mg/kg body weight) was then injected intraperitoneally after 24 and 48 hours to eliminate B
lymphocytes reacting against these antigens. Rats were inoculated intraperitoneally with 107
nonparenchymal liver cells isolated (as described above) from a c129/S3 mouse fed a DDC-
supplemented diet for 3 weeks. Inoculations were administered 19 days (dose #1) and 38
days (boost) after the initial treatment. Four days after the final immunization, animals were
sacrificed and their spleens were harvested. Splenocytes were fused with SP2/0 Ag14
myeloma cells,21 and successfully fused clones were selected by growth in methylcellulose-
containing HAT (hypoxanthine-aminopterin-thymidine) medium (Stem Cell Technologies
Inc., Vancouver, Canada). Approximately 600 isolated clones were transferred to liquid
media in 96-well plates and supernatant was collected for screening by
immunohistochemistry on mouse liver sections and by flow cytometry on dispersed viable
murine NPCs. Clones of interest were passaged to larger culture flasks for increased
antibody production and cryopreservation.
Immunohistochemistry
Cryosections (5 μm) of mouse liver tissue were prepared using a Reichert 2800 Frigocut
(Reichert Scientific Instruments) and fixed by 10-minute exposure to acetone at −20°C.
After drying, slides were stored at −86°C for up to 1 month. Single antibody labeling was
performed with 100 μL of undiluted hybridoma supernatant for 30 minutes. The slides were
then washed in Dulbecco’s phosphate-buffered saline (DPBS) and labeled with 100 μL of
secondary antibody solution (1:200 dilution of Cy3-conjugated goat anti-rat
immunoglobulin G [IgG; Jackson ImmunoResearch, West Grove, PA]), 2% FBS (Hyclone),
and 2% mouse serum in DPBS) for 20 minutes. DPBS was used for a final wash and storage
of the slides prior to microscope evaluation using a Zeiss Axioskop 2 plus (Carl Zeiss, Jena,
Germany). For dual antibody labeling, pre-treatment with avidin/biotin blocking solution
(Vector Labs) was followed by incubation with the first primary antibody as described
above. This antibody was detected by sequential labeling with biotinylated monovalent goat
anti-rat IgG fragment (Jackson ImmunoResearch) and Alexa488-conjugated streptavidin
(Invitrogen). After washing, the second primary antibody was added and detected with Cy3-
conjugated goat anti-rat IgG as indicated above.
Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS)
Dissociated cells were resuspended in 100 μL DPBS plus 2% FBS, combined with an equal
volume of hybridoma supernatant, and stored at 4°C for 30 minutes. After a wash with cold
DPBS, the cells were resuspended in 100 μL DPBS plus 2% FBS and a 1:200 dilution of
fluorochrome-conjugated goat anti-rat secondary antibody (Jackson ImmunoResearch).
After another wash, cells were resuspended in DPBS + 5% rat serum (Serotec) and held on
ice for 10 minutes to block the secondary antibody. Primary conjugated antibodies included
fluorescein isothiocyanate–conjugated anti-CD26 (clone H194-112), phycoerythrin (PE)-
conjugated anti-c-kit (clone 2B8), and allophycocyanin-conjugated anti-CD45 (clone 30-
F11; all BD Pharmingen). Propidium iodide staining was used to label dead cells for
exclusion. Cells were analyzed using a Becton Dickinson FACSCalibur or sorted with a
Cytopeia inFluxV-GS; where possible, electronic gating was used to exclude cell doublets
(by forward scatter:pulse-width ratio) from analysis or collection.
RNA Isolation and Real-Time Polymerase Chain Reaction (PCR)
For molecular analysis, populations of interest were sorted directly into Trizol (Invitrogen).
RNA was isolated with a chloroform extraction, isopro-panol precipitation, and ethanol
wash. First-strand complementary DNA synthesis was generated by Moloney murine
leukemia virus reverse transcriptase and random oligonucleotide primers (Invitrogen). RNA
levels were assessed by quantitative real-time PCR using a Bio-Rad iCycler thermocycler
with a single-color MyiQ detection system. All reactions were performed using 45 cycles of
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15 seconds at 95°C, 18 seconds at 67°C, and 18 seconds at 72°C. Reaction mixtures
included Platinum Taq DNA polymerase (Invitrogen), 2.5 mM MgCl2, 10 μM 5′ and 3′
primers, 10 mM deoxynucleotide triphosphates and 0.5′ SYBR green. The primers
employed were: albumin (5′: TGTCAACCCCAACTCTCGTGGA, 3′:
CACACGGTTCAGGATTGCAGACA), alpha-fetoprotein (5′:
CCAGGCACTGTCCAAGCAAAGC, 3′: TCTTCCCGGTGAGGTCGATCAG), CK7 (5′:
CTGGAGGTGGAACTGCGGAACA, 3′: CGTGCG-TCGGTTGATCTCCTCT), CK19 (5′:
GCCGAGAA-GAACCGGAAGGATG, 3′: CAGCTCCTCAATCCG-AGCAAGGT),
glyceraldehyde 3-phosphate dehydrogenase (5′: AAGGTCGGTGTGAACGGATTTGG, 3′:
CGT-TGAATTTGCCGTGAGTGGAG), von Willenbrand factor (5′:
TGTGGGCTGTGCGGTGATTTTA, 3′: TGGGAGGAGATGCCCGTTTACA), and desmin
(5′: GAGAAACCAGCCCCGAGCAAAG, 3′: AGC-CTCGCTGACAACCTCTCCA). Each
primer pair was designed to span an intron, thus minimizing amplification of contaminating
genomic DNA. Gene expression levels were recorded as the difference between baseline-
corrected, curve-fitted cycle thresholds for the gene of interest minus the cycle threshold of
mouse glyceraldehyde 3-phosphate dehydrogenase.
Results
Monoclonal Antibody Production
Rats were immunized with NPCs from a DDC-treated mouse to increase representation of
rare populations such as oval cells. Subtractive immunization was used to reduce the
contribution of undesired antigens.20 To maximize cell recovery from DDC-treated liver,
which is resistant to perfusion and ex vivo tissue digestion, a four-stage cell isolation
protocol was employed.
Hybridoma supernatants were first screened for selective activity against acetone-fixed
mouse liver tissue sections, but only those that also bound the surface of viable dissociated
single cells as demonstrated by flow cytometric analysis were analyzed further. Table 1 lists
hybridomas that met these criteria and reproducibly recognized cell subsets of interest. In
each case, positively labeled cells were more abundant in DDC-treated than in untreated
tissue, but the recovery of such cells varied from sample to sample as indicated.
Characterization of Hepatic Cell Subset Labeling
Several antibodies gave differential labeling between normal and DDC-treated liver tissue as
shown in Fig. 1. Duct marker macrophage inhibitory cytokine-1–1C3 (MIC1-1C3) (Fig.
1A,B) labeled many more cells in DDC- treated tissue as a consequence of ductal
proliferation. This trend was also true for duct markers oval cell-2–1D11 (OC2-1D11) (Fig.
1E,F) and OC2-2F3 (Fig. 1I,J), but these antibodies did not detectably label ducts in the
absence of DDC treatment. This may indicate specificity for proliferating duct cells.
Periductal markers also fell into two categories based on the extent to which normal tissue
was labeled. OC2-1C6 (Fig. 1C,D), OC2-2A6 (Fig. 1G,H), and OC2-6E10 (Fig. 1Q,R)
bound antigens that are rare in normal tissue but become much more abundant upon oval
cell activation. In contrast, OC2-3C5 (Fig. 1K,L), OC2-3C7 (Fig. 1M,N), and OC2-4E8
(Fig. 1O,P) recognized antigens in untreated liver but did so to a greater extent with DDC
treatment. The labeling patterns of these antibodies on DDC-treated tissue were also
compared with that of the classic oval cell activation marker A6, as shown in Fig. 2.
MIC1-1C3 (Fig. 2A), OC2-1D11 (Fig. 2C), and OC2-2F3 (Fig. 2E) each label a subset of
A6-positive cells in liver tissue after 21 days of DDC treatment. Very limited colabeling was
observed with OC2-3C5 (Fig. 2F), which identifies some duct cells despite its primarily
periductal pattern. The remaining antibodies recognize A6-negative cells, illustrating that
A6 does not mark all cell types which arise de novo during the oval cell response.
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Figure 3 shows representative examples of viable CD45− NPC labeling by each antibody,
confirming recognition of a surface antigen. Although CD45 has been reported to be
expressed on A6-positive cells,15 the current consensus is that liver progenitors are CD45−.
18,22 The intensity of labeling varied between antibodies, but in each case the frequency of
positively labeled cells was higher in DDC-treated liver. Labeling with MIC1-1C3 proved to
be more complicated in the latter, with a small subpopulation of brightly labeled cells (Fig.
3D). A small number of surface markers have previously been reported to bind subsets of
nonhematopoietic mouse liver NPCs, such as Sca-1, CD26, and EpCAM (epithelial cell
adhesion molecule). None of the antibodies reported here have a labeling pattern identical to
these markers, but combined labeling revealed potentially interesting cell subpopulations.
Figure 4 shows combined labeling of commercial antibodies recognizing these established
antigens with the novel antibodies described here. Sca-1, a hematopoietic stem cell marker
reported to be expressed on mouse oval cells,15 was found on a large percentage of CD45−
NPCs in both normal and DDC-treated liver. This differs from the report of Petersen et al.,
who found no Sca-1 expression in normal liver. Comparison to the negative control (Fig.
4A) showed that OC2-1D11+ cells (Fig. 4B) and OC2-3C7+ cells (Fig. 4C) existed in both
Sca-1+ and Sca-1− varieties. Fractionation of the Sca-1+ population with these markers may
facilitate progenitor isolation. Most OC2-1D11+ duct cells coexpressed CD26 (Fig. 4E), but
a subpopulation was CD26−. OC2-3C5, which has a complex labeling pattern including both
periductal cells and a duct cell subset, binds more CD26− than CD26+ cells (Fig. 4F).
EpCAM, which has been reported to be expressed on human liver progenitor cells,23 was
observed on a large proportion of NPCs even in untreated mouse liver (Fig. 4H).
OC2-1D11+ cells, which are rare in untreated liver, appear in both EpCAM+ and EpCAM−
varieties. Thus, our novel antibodies are distinct from those previously described and can be
used in combination to further resolve NPC subpopulations.
Because large numbers of hematopoietic cells copurify with liver NPCs, particularly with
DDC treatment, we investigated the tissue specificity of these antibodies. Most did not bind
hematopoietic cells, as illustrated by the negative binding of OC2-1C6 to bone marrow cells
(Fig. 5B). The exceptions are OC2-2F3 (Fig. 5C), which recognized a subset of marrow
cells (in addition to a subset of liver NPCs), OC2-4E8 (Fig. 5D), in which very weak
labeling was observed on marrow, and OC2-6E10 (Fig. 5E). Furthermore, the duct marker
MIC1-1C3 was also found to specifically label ducts in the pancreas (data not shown).
Dynamics of Antigen Expression During Oval Cell Activation
The DDC-induced murine oval cell response includes inflammation, progressive ductal
proliferation, and the accumulation of oval cells over a period of 3 weeks. Antibodies that
exhibited changes in the extent or type of labeling in this interval are presented in Fig. 6;
CK19 labeling of ducts is shown for comparison. Colabeling of CK19 and the new
antibodies is similar to that of A6; OC2-1D11+ and OC2-2F3+cells are CK19+, and the other
antibodies recognize CK19− cells. One exception is OC2-3C7, which recognizes CK19+ and
some CK19− periductal cells in untreated liver but only CK19− cells after DDC treatment.
In general, signals were rare but detectable at early time points and became more extensive
over time, reaching a maximum at day 21. However, OC2-3C7 binding was already
maximal at day 3, indicating an early response to DDC treatment. Conversely, binding by
duct subset marker OC2-2F3 exhibited a delayed response and was not readily detected until
day 21. Another pattern was demonstrated by OC2-6E10 binding, which reached a
maximum at day 14 and declined by day 21. This may indicate down-regulation of the
associated antigen or loss of a transiently activated OC2-6E10+ population. These labeling
patterns were consistent in multiple sections from different animals. Any variation observed
was also reflected in the detection of CK19.
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Molecular Characterization of Liver Cell Subpopulations
Relevant gene expression levels in antibody-de-fined liver cell populations are listed in
Table 2. These populations were compared with normal hepatocytes and unfractionated
NPCs from a DDC-treated animal. As expected, a comparison of MIC1-1C3+and
MIC1-1C3− NPCs isolated from untreated liver revealed higher levels of duct-associated
genes CK7 and CK19 in the former. Interestingly, this trend was much weaker when
MIC1-1C3 was used to separate NPCs from DDC-treated liver. Each sorted DDC-treated
NPC fraction contained detectable messenger RNA associated with multiple hepatic
lineages, suggesting the presence of multiple cell types or that some of the cells within these
populations coexpressed markers of multiple lineages. OC2-1D11+NPCs, which also
showed no enrichment of duct-associated gene expression despite a cholangiocyte labeling
pattern by immunohistochemistry, had elevated alpha-fetoprotein messenger RNA
suggestive of a progenitor-associated population. Combined labeling with multiple
antibodies should permit a greater degree of cell type enrichment, and single-cell
quantitative PCR should determine whether individual cells coexpress duct and hepatocyte
markers.
Discussion
Here, we present the development of a panel of novel antibodies raised against hepatic NPCs
from mice undergoing oval cell activation. We used a nonbiased cell immunization
technique not aimed at specific antigens, but using the cell population of interest and
screening for differential labeling of normal and oval cell activated liver tissue. This is
analogous to the approach used successfully for the development of most blood cell surface
markers in use for clinical applications and research today.24,25 Although the genes
encoding antigens recognized by the vast majority of CD monoclonal antibodies (CD4,
CD8, CD34, CD45, etc.) were not isolated until many years later,26 these antibodies have
proved crucial in the delineation of the immune system and hematopoiesis.27 Specifically,
surface markers facilitated understanding of the complex heterogeneity of different cell
types and their function in these organ systems. Research on solid organ stem cells,
including hepatic progenitors, has been hampered by the lack of availability of similar
reagents. The antibodies developed herein represent a first step toward resolving questions
regarding cellular heterogeneity within the liver. It is clear from a simple
immunohistochemistry time course during DDC-induced cell activation that it is an
oversimplification to regard “oval cells” as a homogeneous entity; at least two different new
cell types emerge during this injury. First, there is proliferation of a cell type with ductular
characteristics, delineated by MIC1-1C3, OC2-1D11, and OC2-2F3 labeling. OC2-1D11+
and OC2-2F3+ cells are undetectable or absent without DDC treatment, suggesting that these
cells are distinct from normal cholangiocytes or that the associated antigens are expressed as
a consequence of proliferation. Another class of cells (positive for OC2-1C6, OC2-2A6, or
OC2-6E10) is rare or absent in normal liver but appear in abundance in a periductal position
during the oval cell activation process. It is not clear that these cells are a homogeneous
group; for example, OC2-6E10+ cells are detectable at day 3 whereas OC2-2A6+ cells are
absent before day 7. Which of these populations contains the classical “oval cells”, the
bipotential precursor to both hepatocytes and bile ducts? Oval cells in the rat are fairly
distinct from simple ducts in their morphology28 and thus the periductal cells seen here in
the mouse may be most the analogous cell type. Future studies will be needed to determine
the exact nature of the different cells delineated by the antibodies reported here.
We demonstrated the utility of the antibodies not only for immunohistochemistry, but also
for cell separation in protease digested single-cell suspensions. Double-staining with
commercially available anti-blood antibodies clearly showed that the new markers are not
redundant with existing antibodies and can be used to further fractionate populations such as
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Sca-1+ cells. It is important to note that the antigenically distinct populations identified by
FACS may not correspond exactly to the immunohistochemical marking. There are several
reasons for this. First, the cell preps used for FACS are obtained using a fairly harsh
protease digestion. Fragile cells may therefore be underrepresented or even absent in the
NPC fractions used for FACS. Conversely, some cell types may not be efficiently dispersed
to a single-cell state, despite the optimized protocol employed; these would be lost during
filtration and/or rejected by the flow cytometer during electronic gating. Finally, protease
action may also remove some antigens from the surface of weakly positive cells, thus
generating “false negative” cells. As a result, positively labeled cell fractions may prove to
be more consistent and therefore useful than their negative counterparts. Preliminary
experiments with short-term culture revealed no evidence of the “recovery” of detectable
antigen, but protease-induced antigen loss remains a theoretical concern.
We performed a partial characterization of FACS-sorted populations by quantitative PCR of
specific genes of interest. This analysis demonstrated different patterns of gene expression
for distinct antigenically defined populations of liver cells and thus validated the notion of
significant cellular heterogeneity. The discrepancy between NPCs from DDC-treated and
untreated liver when cells were isolated using the duct-labeling antibody MIC1-1C3 is
interesting, and suggests duct heterogeneity or significant changes in gene expression during
ductal proliferation. Indeed, several of the populations isolated from DDC-treated NPCs
exhibit surprising gene expression patterns. A future comparison of these populations
isolated from liver exposed to different stimuli (including alternative oval cell activation
models) will establish the extent to which this is a specific consequence of the DDC model.
It should be emphasized, however, that these differences in do not necessarily indicate the
existence of completely separate cell lineages. Instead, the expression of the antigens may
reflect different stages of maturation in the same lineage.
Much work remains to be done to fully exploit the antibodies described here. With these
novel reagents, it is possible to perform microarray analysis of distinct liver cell populations
during the oval cell response and in normal liver. These studies may discover the
mechanisms of intercellular signaling that govern oval cell activation. Similarly, the
proliferation and differentiation potentials of specific populations within the liver can be
assayed by tissue culture and transplantation experiments. In analogy to what has been
achieved in the hematopoietic system, it may even become possible to purify the elusive
liver stem cell itself.
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Abbreviations
DDC 3,5-diethoxycarbonyl-1,4-dihydrocollidine
DPBS Dulbecco’s phosphate-buffered saline
FBS fetal bovine serum
NPC nonparenchymal cell
PCR polymerase chain reaction
PE phycoerythrin
Dorrell et al. Page 7
Hepatology. Author manuscript; available in PMC 2011 June 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
References
1. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006; 43:S45–S53. [PubMed:
16447274]
2. Crosby HA, Hubscher S, Fabris L, Joplin R, Sell S, Kelly D, et al. Immunolocalization of putative
human liver progenitor cells in livers from patients with end-stage primary biliary cirrhosis and
sclerosing cholangitis using the monoclonal antibody OV-6. Am J Pathol. 1998; 152:771–779.
[PubMed: 9502419]
3. Yang S, Koteish A, Lin H, Huang J, Roskams T, Dawson V, et al. Oval cells compensate for
damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.
Hepatology. 2004; 39:403–411. [PubMed: 14767993]
4. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma.
Gastroenterology. 2004; 127:S97–S103. [PubMed: 15508109]
5. Alison MR. Liver stem cells: implications for hepatocarcinogenesis. Stem Cell Rev. 2005; 1:253–
260. [PubMed: 17142862]
6. Shinozuka H, Lombardi B, Sell S, Iammarino RM. Early histological and functional alterations of
ethionine liver carcinogenesis in rats fed a choline-deficient diet. Cancer Res. 1978; 38:1092–1098.
[PubMed: 76508]
7. Paku S, Schnur J, Nagy P, Thorgeirsson SS. Origin and structural evolution of the early proliferating
oval cells in rat liver. Am J Pathol. 2001; 158:1313–1323. [PubMed: 11290549]
8. Lanier LL, Engleman EG, Gatenby P, Babcock GF, Warner NL, Herzen-berg LA. Correlation of
functional properties of human lymphoid cell subsets and surface marker phenotypes using
multiparameter analysis and flow cytometry. Immunol Rev. 1983; 74:143–160. [PubMed: 6226586]
9. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic
stem cells. Science. 1988; 241:58–62. [PubMed: 2898810]
10. Dunsford HA, Sell S. Production of monoclonal antibodies to preneoplastic liver cell populations
induced by chemical carcinogens in rats and to transplantable Morris hepatomas. Cancer Res.
1989; 49:4887–4893. [PubMed: 2474376]
11. Dunsford HA, Karnasuta C, Hunt JM, Sell S. Different lineages of chemically induced
hepatocellular carcinoma in rats defined by monoclonal antibodies. Cancer Res. 1989; 49:4894–
4900. [PubMed: 2474377]
12. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H, Thorgeirsson SS. Atypical
ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-
diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab
Invest. 1999; 79:103–109. [PubMed: 10068199]
13. Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, Knight B, et al. A modified
choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse
liver. Hepatology. 2001; 34:519–522. [PubMed: 11526537]
14. Faktor VM, Engel’gardt NV, Iazova AK, Lazareva MN, Poltoranina VS, Rudinskaia TD. Common
antigens of oval cells and cholangiocytes in the mouse. Their detection by using monoclonal
antibodies [in Russian]. On-togenez. 1990; 21:625–632.
15. Petersen BE, Grossbard B, Hatch H, Pi L, Deng J, Scott EW. Mouse A6-positive hepatic oval cells
also express several hematopoietic stem cell markers. Hepatology. 2003; 37:632–640. [PubMed:
12601361]
16. Jin C, Li W, Xu F, Zhu J, He Z, Hu Y. Blocking SCF/c-Kit signal did not inhibit the proliferation
of cultured liver progenitor cells. IUBMB Life. 2007; 59:458–464. [PubMed: 17654122]
17. Tsuchiya A, Heike T, Baba S, Fujino H, Umeda K, Matsuda Y, et al. Sca-1+ endothelial cells
(SPECs) reside in the portal area of the liver and contribute to rapid recovery from acute liver
disease. Biochem Biophys Res Commun. 2008; 365:595–601. [PubMed: 17981147]
18. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M. The origin and liver
repopulating capacity of murine oval cells. Proc Natl Acad Sci U S A. 2003; 100(Suppl 1):11881–
11888. [PubMed: 12902545]
Dorrell et al. Page 8
Hepatology. Author manuscript; available in PMC 2011 June 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
19. Overturf K, Al-Dhalimy M, Tanguay R, Brantly M, Ou CN, Finegold M, et al. Hepatocytes
corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.
Nat Genet. 1996; 12:266–273. [PubMed: 8589717]
20. Williams CV, Stechmann CL, McLoon SC. Subtractive immunization techniques for the
production of monoclonal antibodies to rare antigens. Biotechniques. 1992; 12:842–847.
[PubMed: 1642892]
21. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined
specificity. Nature. 1975; 256:495–497. [PubMed: 1172191]
22. Kamiya A, Gonzalez FJ, Nakauchi H. Identification and differentiation of hepatic stem cells during
liver development. Front Biosci. 2006; 11:1302–1310. [PubMed: 16368517]
23. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, et al. Isolation of multipotent
progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal
lineages. Proc Natl Acad Sci U S A. 2006; 103:9912–9917. [PubMed: 16782807]
24. Raff MC. Surface antigenic markers for distinguishing T and B lymphocytes in mice. Transplant
Rev. 1971; 6:52–80. [PubMed: 4108877]
25. Sunderland CA, McMaster WR, Williams AF. Purification with monoclonal antibody of a
predominant leukocyte-common antigen and glycoprotein from rat thymocytes. Eur J Immunol.
1979; 9:155–159. [PubMed: 374095]
26. Kitamura K, Matsuda A, Motoya S, Takeda A. CD45-associated protein is a lymphocyte-specific
membrane protein expressed in two distinct forms. Eur J Immunol. 1997; 27:383–388. [PubMed:
9045908]
27. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem
cell. Am J Pathol. 2006; 169:338–346. [PubMed: 16877336]
28. Sells MA, Katyal SL, Shinozuka H, Estes LW, Sell S, Lombardi B. Isolation of oval cells and
transitional cells from the livers of rats fed the carcinogen DL-ethionine. J Natl Cancer Inst. 1981;
66:355–362. [PubMed: 7005506]
Dorrell et al. Page 9
Hepatology. Author manuscript; available in PMC 2011 June 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
Antibody labeling of cell subsets in normal and DDC-treated mouse liver tissue. Mouse liver
cryosections (5 μm) were labeled with supernatants from hybridoma cell lines with liver cell
subset specificity. For each antibody, labeling on normal liver tissue (left) is compared to
that of liver from a mouse fed a DDC-supplemented diet for 3 weeks (right). The secondary
antibody was Cy3-conjugated anti-rat IgG adsorbed against mouse serum protein; nuclei
were labeled with Hoechst 33342. Original magnification: 200×, inset: 1600×.
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Fig. 2.
Comparative labeling with the A6 oval cell marker on DDC-treated mouse liver tissue.
Acetone-fixed cryosections were labeled with both A6 antibody (red) and the indicated
antibody (green). Because each primary antibody is an unconjugated rat IgG, sequential
labeling and a monovalent initial secondary antibody were employed. Nuclei were labeled
with Hoechst 33342.
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Fig. 3.
Flow cytometric assessment of binding to viable dissociated mouse liver cells. Dead cells
were excluded by gating for propidium iodide negative events; hematopoietic cells were
excluded by gating for CD45− events; and debris, cell clusters, erythrocytes, and
hepatocytes were excluded by FSC/SSC gating. NPCs from normal and DDC-treated livers
were sequentially labeled with the primary antibody and a PE-conjugated anti-rat IgG
secondary antibody. The indicated gate for PE-positive events was set based on the negative
control samples (A,B).
Dorrell et al. Page 12
Hepatology. Author manuscript; available in PMC 2011 June 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Novel antibody labeling on liver NPCs is distinct from that of previously reported
antibodies. (A,D,G) Negative controls indicate labeling with isotype control antibodies.
Examples of comparative labeling with the antibodies described here and (B,C) Sca-1, (E,F)
CD26/DPPIV, or (H) EpCAM are shown. EpCAM versus OC2-1D11 labeling is shown for
(G,H) NPCs from untreated liver, whereas (A–F) the Sca-1 and CD26 comparisons used
DDC-treated NPCs.
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Fig. 5.
A subset of antibodies binds hematopoietic cells. Bone marrow cells were collected from a
mouse femur and labeled with the indicated antibodies. A small amount of nonspecific
labeling was observed with (A) the secondary antibody alone or (B) with primary antibodies
that do not bind marrow cells (for example, OC2-1C6). Plots in (C–E) illustrate positive
labeling by the antibodies that recognize subsets of hematopoietic cells.
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Fig. 6.
Antibody labeling patterns change during oval cell activation. Cryosections of liver tissue
obtained from mice after the indicated duration of DDC treatment were labeled with OC2
antibody supernatants (red) and rabbit anti-mouse CK19 (green). Secondary antibodies
included Cy3-conjugated goat anti-rat IgG and Alexa488-conjugated donkey anti-rabbit
IgG. Nuclei were labeled with Hoechst 33342. Original magnification: 200×, inset: 1600×.
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Table 1
Monoclonal Antibodies Recognizing Surface Antigens on Subsets of Mouse Liver Cells
Antibody Isotype Classification
Percent of CD45- Liver NPCs Positive
Untreated DDC-treated
MIC1-1C3 rat IgM Ductal 8–24 19–60
OC2-1C6 rat IgG1 Periductal <1 4–30
OC2-1D11 rat IgG1 Ductal 0–10 14–60
OC2-2A6 rat IgG1 Periductal <1 2–29
OC2-2F3 rat IgG1 Ductal <1 1–21
OC2-3C5 rat IgG1 Periductal + 5–22 21–58
OC2-3C7 rat IgG1 Periductal 1–7 2–10
OC2-4E8 rat IgG1 Periductal 0–10 22–48
OC2-6E10 rat IgG1 Periductal <1 1–11
Antibody labeling patterns are classified as ductal or periductal based on specificities observed on liver tissue sections. The ranges of cell labeling
frequencies are based on the evaluation of four CD45- NPC preparations by flow cytometry.
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